Hepatocellular Carcinoma: A Pharmacological Aspect by Sharma, Mani et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
Hepatocellular Carcinoma: A 
Pharmacological Aspect
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Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, 
deteriorating approximately 1000,000 lives. Annually rising HCC to the third most 
common cause of cancer mortality. Liver cancer varies geographically depend-
ing on multimodality treatments available for this heterogeneous malignancy. 
Conglomeration of treatments has been exercised to manage this type of cancer 
across distinct geographic regions. Unprecedented rise of scientific knowledge 
mining from the published literature is a boon to develop novel treatment modali-
ties. We aim to focus such pharmacological aspects in HCC treatment that could 
effectively display the improved therapies. Extrapolating the details of liver cancer 
(classification, diagnosis, adequate treatments, therapeutic engineering involved 
in the therapy, causes, epidemiology, and survival ratio) and the result obtained 
through this research could be a magnificent approach in the advancement of 
drug delivery systems that could assist in clinical trials and further betterment of 
 survival rate and improved therapy from this deadly cancer.
Keywords: category, symptoms, prognosis, pathophysiology, remedies,  
therapeutic engineering
1. Introduction
As per the current study performed by the international agency for research on 
cancer (World Health Organization), the number of liver cancer cases reported all 
over the globe was 841,080, i.e., 4.7% of the total cancer cases in year 2018. As per 
the reports of the American Cancer Society, there is an estimation of 42,030 new 
cases of liver cancer diagnosed in the United States alone for the year 2019. Three-
fourths of those cases are of hepatocellular carcinoma (HCC) that is unquestionably 
the most serious and dreaded complication of chronic liver disease. The development 
of HCC is generally the terminal event of a long-standing, typically asymptomatic 
chronic liver disease, which originated decades earlier. Regardless of the etiology, 
the process begins with a frequently unrecognized acute or subacute liver insult that 
slowly advances to the development of cirrhosis, a potentially preneoplastic condi-
tion. Less commonly, HCC arises directly without antecedent cirrhosis. The average 
life expectancy after diagnosis of clinically apparent HCC is less than 12 months [1].
People with chronic liver diseases, such as cirrhosis caused by hepatitis B 
or hepatitis C infection, are most often prone to hepatocellular carcinoma. 
Hepatocellular carcinoma is traditionally related to liver cirrhosis and also with the 
ongoing process of liver necrosis or regeneration, where liver cirrhosis may be due 
to hepatitis B and C.
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In regions of Africa, Asia, and China, intake of food contaminated with  
aflatoxins may be later associated with HCC, while in Europe only 30% of pediatric 
HCC cases are linked to liver cirrhosis, while others are de novo cases [2] .  
As per the report of the American Cancer Society, 31,780 liver cancer deaths 
occurred in the United States alone for the year 2019. Incidence rates (%) in total 
population the disease is approximately 2.5 per 100,000 population [3]. It is one of 
the most common malignancies in adults and is more common in men than women 
(2–4:1) and blacks than whites. All over the world, millions of deaths per year 
(about 10% of all deaths in the adult age range) can be attributed to hepatocellular 
carcinoma. Depending on geographic location, the occurrence of hepatocellular 
carcinoma varies. While incidence in the Western world is less than 2 per 100,000 
males, it is currently 40–60 per 100,000 in Africa and parts of the Far East. People 
of East Asian origin suffers the most from Hepatocellular carcinoma in United 
States. In the future, the prevalence of hepatocellular carcinoma may increase in the 
United States.
People with long-term liver diseases are most vulnerable to the risk of hepa-
tocellular carcinoma. As people who already have signs and symptoms of chronic 
liver disease are majorly suffering from HCC. Prolonged yellow skin, easy bruis-
ing from blood clotting abnormalities, abdominal swelling, appetite loss, weight 
loss, pain in the abdominal cavity, nausea, feeling tired, or vomiting may be 
directly associated with HCC [4]. The mortality rate of the patients (both sexes) 
suffering from liver around the world in 2018 is 781,631. Among which 72.4% 
of the total mortality cases were recorded in Asia. As per the current statistics, a 
comprehensive approach is urgently required that involves primary and secondary 
prevention and increased access to treatment, and more funding for liver-related 
research is needed to address the high death rates associated with chronic liver 
disease and liver cancer to decrease the average mortality rate by giving adequate 
treatments.
1.1 Risk factors
Cirrhosis of the liver mostly causes HCC, whereas other factors also majorly 
influence the risk of HCC among which 60–70% of cirrhosis is estimated to cause 
by heavy alcohol consumption (Figure 1).
Recognized risk factors include:
• Toxins: alcohol abuse, aflatoxin, iron overload state (hemochromatosis)
• Metabolic: nonalcoholic steatohepatitis, type 2 diabetes (probably aided by 
obesity)
There is a variable significance of these risk factors globally [5]. In regions where 
hepatitis B infection is endemic, such as southeast China, this is the predominant 
cause. In populations largely protected by hepatitis B vaccination, such as the 
United States, HCC is most often linked to causes of cirrhosis such as chronic 
hepatitis C, alcohol abuse, and obesity. The chance of developing HCC in children 
and adolescents increases if they suffer from congenital liver disorders.
1.2 Symptoms
Patients with hepatocellular carcinoma are frequently asymptomatic especially 
if the disease is diagnosed at an early stage. The major symptoms include abnormal 
weight loss, mild to high fever, diarrhea, fatigue, and anorexia [6].
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Symptomatic patients—Patients with advanced lesions may present with mild to 
moderate upper abdominal pain, weight loss, early satiety, or a palpable mass in the 
upper abdomen [7]. Paraneoplastic syndrome may occasionally develop in a patient 
with HCC [8].
Hypoglycemia—Hypoglycemia, which usually occurs in advanced HCC, is 
thought to result from the tumor’s high metabolic needs.Erythrocytosis—Tumor 
secretion of erythropoietin (EPO) majorly leads to erythrocytosis in HCC [9].
Hypercalcemia— Hypercalcemia can be present in association with osteolytic 
metastases, but it may also be seen in the absence of bony metastasis due to secre-
tion of parathyroid hormone-related protein [10].
Diarrhea—Patients with HCC may infrequently present with intractable diar-
rhea and associated electrolyte disturbances (e.g., hyponatremia, hypokalemia, 
metabolic alkalosis). The underlying mechanism is not fully understood, but it may 
be related to secretion of peptides that cause intestinal secretion. These include 
vasoactive intestinal polypeptide, gastrin, and peptides with prostaglandin-like 
immunoreactivity [11].Cutaneous features—Although skin changes are rare in 
patients with HCC, several cutaneous manifestations have been described; however, 
none is specific for the diagnosis [12].
It involves the following:
• Dermatomyositis may present with a variety of cutaneous findings (e.g., scaly, 
violaceous papules overlying bony prominences of the hands) and is associated 
with solid organ malignancies.
• Pemphigus foliaceus is a superficial blistering disease similar to pemphigus 
vulgaris, except it rarely involves the mucous membranes. Blisters often appear 
as shallow erosions associated with erythema, scale, and crust formation, and 
the appearance may resemble severe seborrheic dermatitis.
• Sudden appearance of multiple seborrheic keratosis is the sign of Leser-Trélat, 
with acanthosis nigricans and skin tags.
• Multiple, round, or oval, sharply demarcated scaling patches have been 
reported in South African black patients with HCC characterized as Pityriasis 
rotunda [13].
Figure 1. 
Risk factors leading to the cause of HCC: (a) estimated cause of 80% cases globally, (b) alcohol abuse, 
aflatoxin; iron overload state (hemochromatosis); (c) alpha 1-antitrypsin deficiency; Wilson’s disease.
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Other clinical presentations that may be seen in symptomatic patients with HCC 
are as follows.
A. Intraperitoneal bleeding due to tumor rupture. Tumor rupture is often 
associated with sudden onset of severe abdominal pain with distension and 
an acute drop in the hemoglobin and hypotension and is most commonly 
diagnosed by imaging the abdominal parts. A liver mass and free intraperi-
toneal blood can be demonstrated by doing computed tomography of the 
abdominal part [14]. Emergency angiography and embolization is required 
in case of bleeding as it can become a life-threatening complication [15]. If 
feasible, delayed resection may be considered although the risk of peritoneal 
dissemination is high [16].
B. Obstructive jaundice majorly caused by invasion of the biliary tree or due to 
compression of the intrahepatic duct.
C. Fever developing in association with central tumor necrosis.
D. Pyogenic liver abscess (very rare) [17].
1.3 Diagnosis
Early diagnosis of HCC is through screening or surveillance and is in treat-
able stage. Typically ultrasonography is performed every 6 months in screening 
and surveillance for abdominal imaging. A cross-sectional imaging of a detected 
nodule through ultrasonography using triple-phase CT or contrast-enhanced MRI 
is performed frequently. Increased tumor vascularity is observed in the arterial 
phase by radiographic features of HCC. Tumor invasion of the portal vein or lymph 
node enhancement identification is an additional imaging feature. Liver Imaging 
Reporting and Data System (LIRADS) systematically characterize these imaging 
findings diagnostic criteria that also incorporates tumor growth [18]. The resem-
blance of to normal hepatocytes to neoplastic cells assesses the degree of differen-
tiation of HCC [19].
The possibility of tumor seeding during the biopsy, and the patients with 
chronic kidney disease represent a particular challenge since MRI contrast agents 
are contraindicated in end-stage renal disease given the risk of renal toxicity [20].
The evaluation after HCC diagnosis is done through different techniques.
A multidisciplinary setting is required to select therapy after the diagnosis 
of HCC is made for further evaluations. History and physical examination and 
serologic and imaging tests are obtained to assess the patient’s liver reserve, perfor-
mance status, comorbidities, extent of tumor spread, and potential eligibility for 
liver transplantation. “Staging and prognostic factors in hepatocellular carcinoma” 
are the Multidisciplinary evaluations [21].
1. Surgical resection
2. Liver transplantation
3. Locoregional therapies
4. Ablative therapies (radiofrequency ablation, microwave ablation,  
cryoablation)
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5. Percutaneous ethanol or acetic acid ablation
6. Irreversible electroporation
7. Transarterial embolization (bland embolization, chemoembolization, radio-
embolization)
8. External beam radiotherapy
9. Systemic chemotherapy and immunotherapy
10. Laboratory tests—Complete blood count, platelets, renal function tests, pro-
thrombin time, albumin
11. Liver biochemical and function tests (i.e., bilirubin, aminotransferases, alka-
line phosphatase)
12. Imaging—Extent of tumor spread may be evaluated with the following imag-
ing exams:
a. Contrast-enhanced abdominopelvic computed tomography (CT) or 
magnetic resonance imaging (MRI) tailored for liver lesion evaluation (see 
“Modalities for HCC diagnosis” above)
b. Chest CT without or with intravenous contrast.
c. Whole body technetium-99m bone scan, if clinically indicated
2. Pathophysiology of HCC
2.1 Anatomy of the liver
The liver is one of the most complex and largest organs in the abdominal cavity. 
Lobules are the major microscopic functional units of the liver. Removal of endog-
enous and exogenous materials from the blood, carbohydrate homeostasis, complex 
metabolic processes including bile production, lipid metabolism, urea formation, 
and immune functions are some of the major functions performed by the liver. The 
upper posterior surface of the liver is outside of mesogastrium, a structure through 
which liver arises. The liver is connected to the anterior body wall by the ligamen-
tum teres and falciform ligament. It connects to the stomach by the lesser omentum 
and the coronary and triangular ligaments to the diaphragm. The liver is the largest 
internal organ. The position of the liver is just beneath your right lung and under 
your right ribs. It has two lobes (sections) involving the right lobe and the left lobe. 
Women are in more risk to develop hepatic cancer and FNH tumors than men [22] 
(Figure 2).
Another type of cells in the liver called as bile ducts are the cells that line small 
tubes in the liver. The bile ducts carry bile from the liver to the gallbladder or 
directly to the intestines. It has many important functions: it breaks down and 
stores many of the nutrients absorbed from the intestine that your body needs to 
function. It delivers bile into the intestines to help absorb nutrients (especially 
fats). It breaks down alcohol, drugs, and toxic wastes in the blood, which then pass 
from the body through urine and stool. Several types of malignant (cancerous) and 
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benign (noncancerous) tumors can be formed through different types of cells in the 
liver. These tumors generated via different cell origins have different root causes, 
different modes of treatments, and have a different outlook. Hepatitis infection was 
linked to HCC by Beasley in 1981 [23].
2.2 Category of liver cancer
2.2.1 Primary liver cancer
A cancer that starts in the liver is called primary liver cancer that can be more 
than one type.
2.2.1.1 Intrahepatic cholangiocarcinoma (bile duct cancer)
Intrahepatic cholangiocarcinomas covers 10–20% of cancers that start in the 
liver. This type of cancer mostly starts in the bile duct where carcinogenic condi-
tions can be facilitated by the repetitions of inflammation [24].
2.2.1.2 Angiosarcoma and hemangiosarcoma
Cells lining the blood vessels of the liver are the rare causes of liver cancer. 
Exposure to vinyl chloride or to thorium dioxide (Thorotrast) may develop these 
cancers (see Liver cancer risk factors). Some other cases are thought to be caused 
by exposure to arsenic or radium or to an inherited condition known as hereditary 
hemochromatosis. It is difficult to investigate the exact cause for the development 
of cancer cells. These tumors grow quickly and are usually too widespread to be 
removed surgically by the time they are found. The pathogenesis of such HCC is 
made up of different genetic/epigenetic aberrations and alterations with many 
signaling pathways that lead to a known heterogeneity of the diseases’ biologic and 
clinical behavior [25].
Figure 2. 
Anatomy of the liver.
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2.2.1.3 Hepatoblastoma
Children with the age of below 4 years develops this rare form of cancer, that 
usually seen in the younger age. Fetal liver cells are similar to the cells of hepatoblas-
toma. It is harder to treat such tumors if they spread outside the liver, where surgery 
and chemotherapy are the successful therapies in treating two out of three children 
suffering from such a tumor. The genetic pathways that are affecting hepablastoma 
have to be further studied and analyzed [26].
2.2.2 Secondary liver cancer (metastatic liver cancer)
Most of the time when cancer is found in the liver, it did not start there but 
has spread (metastasized) from somewhere else in the body, such as the pancreas, 
colon, stomach, breast, or lung. As this cancer spreads from its original site, it is 
called a secondary liver cancer.
2.2.2.1 Benign liver tumors
Sometimes larger growth of benign tumors causes problems, though they do not 
grow into nearby tissues or do not spread to other distant parts of the body. Surgery 
can be the best therapy for such a kind of cancer.
2.2.2.2 Hemangioma
Hemangiomas start in the blood vessels and are considered another most com-
mon type of liver cancer. They generally do not show any symptoms but need to 
operate in chronic cases Multidetector-row computed tomography (MDCT) [27].
2.2.2.3 Hepatic adenoma
This tumor starts from hepatocytes (the main type of liver cell) with symptoms 
like pain in the abdomen, lump in the stomach area, or blood loss. In such cases 
there is always a risk of tumor rapture or further growth into a vigorous liver cancer. 
Thus, surgery is the most effective treatment advised by the experts. Fibrolamellar, 
pseudoglandular (adenoid), pleomorphic (giant cell), and clear cell are microscopi-
cally, the four architectural and cytological types (patterns) of hepatocellular 
carcinoma [28].
2.3 Remedies and treatment (staging)
Patients with cirrhosis and varying degrees of hepatic dysfunction are majorly 
prone to HCC. A careful assessment of hepatic function in addition to tumor 
parameters is thus required for the adequate treatment of HCC. Patients are often 
managed by multidisciplinary teams at tertiary referral medical centers (Figure 3).
2.3.1 Drugs in market and drugs under clinical trial
Various chemotherapeutic potent drugs for the treatment of HCC have been 
efficiently developed, and many are in the pipeline under different phases of clini-
cal trials. A brief enlisting of such drugs approved by the FDA and under clinical 
trials is depicted in Tables 1 and 2 [29].
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2.4 Therapeutic engineering
The following therapeutic treatment engineering options are available to 
patients with hepatocellular carcinoma (Figure 4).
S. no. Drugs Company Approved year
1 Sorafenib (Nexavar) Bayer and Onyx 2007 in the United States
2 Regorafenib (Stivarga) Bayer 2017 in the United States
3 Nivolumab (Opdivo) Bristol-Myers Squibb 2017 in the United States
4 Lenvatinib (Lenvima) Eisai Co. 2018 in the United States
5 Cabozantinib (Cabometyx) Exelixis Inc. 2018 in Europe
6 Pembrolizumab (Keytruda) Merck 2018 in the United States
7 Pembrolizumab Merck 2018 in the United States
8 Rozlytrek (entrectinib) Roche 2019 in the United States
9 Cabozantinib (Cabometyx) Exelixis 2019 in the United States
10 Ramucirumab (Cyramza) Eli Lilly 2019 in the United States
11 Atezolizumab TECENTRIQ® 2019 in the United States
Table 1. 
Recently approved drugs for the treatment of HCC [29].
Figure 3. 
Potential treatment options for HCC.
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2.4.1 Surgical therapy
Surgery is the treatment of choice for noncirrhotic patients suffering from 
HCC. However, only 20% of patients are potentially resectable at the time of pre-
sentation. In noncirrhotic patients, surgical mortality is less than 3% in experienced 
hands, but increases to 8% in patients with cirrhosis [3].
2.4.2 Liver resection
Surgery provides the best possibility for a cure. For that reason, every patient 
should be evaluated first and foremost for the possibility of resection. Organ removal 
can result in cure in early diagnosis states and overspreading of cancer in other organs.
Unfortunately, not all patients are eligible for liver resection. Resection is not 
indicated when (1) the tumor has spread to other parts of the liver or the body, (2) 
the size or location of the tumor resists the part of liver removal without compro-
mising the total functionality of the organ, (3) the associated cirrhosis or disease 
limits the ability to safely operate upon or remove part of the liver, and (4) other 
medical conditions make surgery unsafe [3].
2.4.3 Cryosurgery
Cryosurgery is a technique utilizing subzero temperatures to destroy tumors. In 
most cases, the tumor is destroyed but not removed. The placement of one or more 
probes (cryoprobe) into the tumor site using ultrasound to guide the placement is 
adopted in such a technique [3] (Figure 5).
Figure 4. 
Hepatocellular carcinoma in healthy cells.
S. no. Drugs Developed by Drugs in clinical trials
1 Milciclib (PHA-848125) Tiziana Life Sciences II Phase
2 Galunisertib (LY2157299) Eli Lilly II Phase
3 Ipafricept (OMP-54F28) OncoMed I Phase
4 Ipilimumab (Yervoy) Bristol-Myers Squibb II Phase
5 Brivanib Bristol-Myers Squibb III Phase
Table 2. 
Drug candidates in the pipeline under different phases of clinical trials [30].
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2.4.4 Radiofrequency ablation
Radiofrequency ablation (RFA) is a new technique that makes use of a “heating” 
probe to destroy tumors within the liver. A probe with thin tip is put into a tumor 
site. After deploying the tip array, an electrical current is applied, generating heat 
(80–100°C) that destroys the tumor (Figure 6).
This kind of technique can be done in an operating room or with a laparoscopic 
approach. RFA is used to treat the tumor, whereas the remaining parts of the tumor 
are removed by surgery.
2.4.5 Liver transplantation
In patients with small tumors and advanced cirrhosis (Child B or Child C) the 
treatment of choice is liver transplantation.
Patients who are not candidates for surgical resection or transplantation should 
be considered for other forms of treatment including cryosurgery, chemoemboliza-
tion, ethanol or cisplatin infusion, or radiofrequency ablation (Figure 7).
2.4.6 Interventional radiological therapy
The most commonly performed procedures in the treatment of unresectable 
liver tumors (i.e., those that are inoperable) are hepatic artery chemoembolization 
and hepatic artery chemoradiation. Most hepatic tumors are supplied by the hepatic 
arterial system, as opposed to normal liver tissue, in which most of the blood supply 
comes from the portal venous system. Chemoembolization is considered superior 
over intravenous pump infusion therapy because it delivers drug with more target 
specification. System toxicity is reduced as 85% of the total drug administered in 
the body is trapped in the liver itself [3] (Figure 8).
Figure 5. 
Cryosurgery of hepatocellular carcinoma.
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2.4.7 Ethanol injection by percutaneous method
Tumors less than 5 cm in diameter and patients with less than three lesions 
can be treated with percutaneous ethanol injection. It has been demonstrated that 
ethanol injection is more effective against hepatoma lesions than against metastatic 
lesions [3] (Figure 9).
Figure 6. 
Radiofrequency ablation in hepatocellular carcinoma.
Figure 7. 
Transplantation of the liver.
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Ultrasound vibrations are used to perform such a procedure. Ethanol is injected 
slowly into a lesion through a small needle that is inserted into the posterior aspect 
of the tumor. Patients may receive one or two sessions per week until the tumor is 
completely saturated. Post-procedural imaging, including CT and MRI, is typically 
conducted after 1 month and then every 4 months thereafter [3].
2.4.8 Percutaneous radiofrequency ablation
Frictional heat produced during percutaneous radiofrequency ablation causes 
destruction to the local tissues. This procedure is also performed under ultrasound 
guidance. A radiofrequency needle is inserted deep into the lesion, and multiple 
electrodes are deployed. The duration of the treatment varies from 6 to 15 minutes. 
Figure 8. 
Hepatic artery chemoembolization.
Figure 9. 
Percutaneous ethanol injection in hepatic tumors.
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Only limited data are available regarding the use of this technique to treat unresect-
able liver tumors, but preliminary studies have shown a trend toward prolonged 
survival [3] (Figure 10).
2.4.8.1 Cisplatin gel infusion percutaneous
Unresectable liver tumors can be treated by cisplatin gel infusion technique that 
is a new and promising therapeutic option [3] (Figure 11).
Clinical trials of this technique are undergoing in the United States as it has been 
recently developed. It is almost similar to percutaneous ethanol injection method. 
This technique is also performed in ultrasound vibrations like the percutaneous 
method. Cisplatin gel is infused into the deepest part of the tumor through a small 
Figure 10. 
Percutaneous radiofrequency ablation in hepatic tumors.
Figure 11. 
Percutaneous cisplatin infusion in hepatic tumors.
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needle. The chemotherapeutic drug is carried slowly by this gel into the tumor 
site. The gel slowly diffuses throughout the tumor and acts as a carrier of the 
 chemotherapeutic drug [3].
3. Conclusion
These explanations and findings show that the etiology of HCC is extremely 
complex, with many confounding factors affecting disease course and patient prog-
nosis. Excessive intake of alcohol, aflatoxin-contaminated food, obesity, and diabe-
tes are the major risk factors for the development of HCC. A better understanding 
of HCC may offer us the best chance of achieving earlier diagnosis and interven-
tion, which would ultimately improve the outlook for those at risk for developing 
HCC. These findings may support future studies in investigating the possibilities, 
developing adequate treatments with intra- and inter-variances of patients in mind, 
and aiming to improve the mortality for individuals with hepatocellular carcinoma.
4. Future directions
Despite many advances, the treatment of hepatocellular carcinoma is unsatisfac-
tory. As per the current clinical data we can expect, gene therapy and immunother-
apy may become more viable for the management and treatment of hepatocellular 
carcinoma in more safe and effective ways.
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